Home > Information
Information
- Nov. 5, 2024
- NCC will initiate new research to develop a nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for cancer patients.
- Sep. 17, 2024
- SCRUM-Japan GOZILA Confirms Extended Survival with Personalized Cancer Treatment in 4,000+ Patients Study
- Sep. 17, 2024
- CIRCULATE-Japan GALAXY Confirms Effectiveness of Liquid Biopsy in Predicting Recurrence Risk and Post-operative Treatment Efficacy in Colorectal Cancer
- Sep. 12, 2024
- Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
- Jun. 11, 2024
- Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System
- Jun. 4, 2024
- NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
- May 23, 2024
- Dr. Shitara was awarded the 5th Japan Research Front Award
- Apr. 30, 2024
- National Cancer Center Hospital East on Newsweek’s “World’s Best Specialized Hospitals (Oncology) 2024”
- Dec. 14, 2023
- National Cancer Center Japan and Japan Investment Corporation (JIC) sign agreement to promote comprehensive collaboration
- Dec. 1, 2023
- Sharing of clinical trial information improves the quality of treatment recommendations by expert panels
- Jul. 21, 2023
- International Robotic D2 Gastrectomy Seminar at NCC Hospital East
- Apr. 19, 2023
- World-first confirmation of standard treatment for RAS wild-type colorectal cancer－Paper published in JAMA－
- Apr. 12, 2023
- Start of Clinical Research of the First Japanese-Produced Next-Generation Photon Counting Computed Tomography
- Jan. 24, 2023
- Clinical Utility of Circulating Tumor DNA After Surgery for Colorectal Cancer Demonstrated in a Large-Scale Prospective Study －A Step toward Personalized Postoperative Adjuvant Chemotherapy－
- Oct. 21, 2022
- Introduction video of National Cancer Center Hospital East has been update
- Sep. 27, 2022
- Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform
- Aug. 4, 2022
- Approximately 43,000 individual patient data of clinical trials with colorectal cancer in Asia and the West shared
- Jun. 8, 2022
- Virtual Meeting with Peking University First Hospital, Celebrating the Conclusion of Memorandum of Understanding
- May 25, 2022
- Cooperation with the U.S. National Cancer Institute welcomed by Japan-US leaders in joint statement- role of National Cancer Center highlighted
- Mar. 24, 2022
- The research article by Dr. Shitara et al. was published in the journal Nature
- Feb. 21, 2022
- Memorandum of Understanding signed with Peking University First Hospital
- Dec. 24, 2021
- We have launched English Website of ARCAD Asia
- Dec. 23, 2021
- Webinar for “Russo -Japanese Joint Symposium”
- Dec. 21, 2021
- CLIP1-LTK fusion: A novel druggable gene fusion in NSCLC,
identified using LC-SCRUM-Asia genomic screening platform - Nov. 12, 2021
- Study shows efficacy of dual-HER2 targeted therapy for patients with HER2-positive colorectal cancer
- Nov. 11, 2021
- First in-patient transplantation of iPS cell-derived natural killer cells to treat ovarian cancer
- Sep. 13, 2021
- Webinar on Clinical Research with Guangxi, China
- Aug. 24, 2021
- Webinar with Guangxi, China
- Aug. 16, 2021
- Webinar with Neijiang, China
- Jun. 30, 2021
- Initiation of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan, SCRUM-Japan
- May 17, 2021
- "MONSTAR-SCREEN" has joined as an official member program in the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC-ARGO)
- May 14, 2021
- NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
- Feb. 2, 2021
- Deep Vision: Near-Infrared Imaging and Machine Learning Can Identify Hidden Tumors
- Oct. 22, 2020
- Webinar with Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College
- Oct. 6, 2020
- Development of Precision Medicine for Gastrointestinal Cancers Utility of Liquid Biopsy in Genomic Analysis
- Aug. 20, 2020
- NCC joins GSK’s oncology development network
- Jun. 22, 2020
- National Cancer Center Japan and Mitsui Fudosan Agree on Accommodation Facility at the National Cancer Center Hospital East in Kashiwa-no-ha Smart City
- Mar. 7, 2019
- Kazakhstan Delegation visit
- Nov. 19, 2018
- Quickening the pace of new anti-cancer agents Attracting nanoparticles full of cancer drugs to the stroma of a tumour is proving key to new therapeutics.
- Nov. 13, 2018
- Hospital East honoured at ESMO
- Aug. 8, 2018
- Dr Masaaki Ito appointed Honorary Professor at China-Japan Friendship Hospital
- Apr. 3, 2018
- Advanced Medical Care Approval Received for Multiplex Gene Panel Testing
to Advancing Personalized Medicine - Mar. 13, 2018
- SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood
- Feb. 14, 2018
- A secondary RET mutation in the activation loop conferring
resistance to vandetanib through allosteric effects